Egetis Therapeutics AB (OSTO:EGTX) Tariff Resilience Score: 0/10 (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:EGTX Egetis Therapeutics AB OSTO:EGTX
68 GF Score
Price kr6.11
GF Value kr5.62
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB Tariff Resilience Score?

Egetis Therapeutics AB has the Tariff Resilience Score of 0, which implies that the company might have .

Egetis Therapeutics AB has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Egetis Therapeutics AB might have .

Egetis Therapeutics AB  (OSTO:EGTX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Egetis Therapeutics AB Tariff Resilience Score Related Terms

OSTO:EGTX
68GF Score
Egetis Therapeutics AB OSTO:EGTX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Egetis Therapeutics AB (OSTO:EGTX) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued. The current stock price of kr6.11 is trading 8.7% above its estimated GF Value™ of kr5.62. GuruFocus considers Egetis Therapeutics AB to be Fairly Valued.

Key valuation signals for OSTO:EGTX:

  • Tariff Resilience Score: 0
  • GF Value™: kr5.62 vs. price of kr6.11 (8.7% above fair value)
  • GF Score™: 68/100 with 8 warning signs

No single metric tells the full story. See the OSTO:EGTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egetis Therapeutics AB Business Description

Other Exchanges PDPHF:USA0ABW:UKP0F:Germany
Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
68GF Score

Get the complete analysis for OSTO:EGTX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr6.11
Price
kr5.62
GF Value